Journal Watch · Frontiers in Immunology · 2026
Identification of public neoantigens with broad HLA class I coverage as candidates for off-the-shelf cancer vaccine development in colorectal cancer.
Our integrative computational and experimental framework highlights the importance of combining population-level HLA coverage with functional validation to advance broadly applicable neoantigen-based immunotherapies.
TL;DR
Our integrative computational and experimental framework highlights the importance of combining population-level HLA coverage with functional validation to advance broadly applicable neoantigen-based immunotherapies.
Key findings
- Neoantigen-reactive T cells exhibited transcriptional signatures consistent with cytotoxic effector function and stem-like memory phenotypes.<h4>Discussion</h4>These findings identify TP53_R273H as a clinically relevant shared neoantigen in CRC and support the translational feasibility of a population-tailored OTS neoantigen panel.
- Our integrative computational and experimental framework highlights the importance of combining population-level HLA coverage with functional validation to advance broadly applicable neoantigen-based immunotherapies.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Functional immunogenicity was assessed in patient-derived CD8⁺ T cells using IFN-γ ELISpot assays and single-cell RNA sequencing.<h4>Results</h4>The resulting panel comprised 73 recurrent nonsynonymous mutations, each generating at least one predicted HLA-I-restricted neoepitope, achieving >90% population coverage in both Asian and Caucasian groups. In the Vietnamese CRC cohort, 58% of patients harbored at least one matched neoantigen, with mutation frequency strongly correlating with predicted HLA presentation, particularly for HLA-A alleles. Functional validation in seven patients demonstrated robust CD8<sup>+</sup> T-cell responses against TP53_R273H.
Full abstract (original)
Background: <h4>Introduction</h4>Shared neoantigens derived from recurrent mutations represent promising targets for off-the-shelf (OTS) cancer immunotherapies; however, their clinical utility is often constrained by population-specific HLA diversity and variable immunogenicity. There remains a need for population-tailored neoantigen panels with broad HLA coverage and functional validation.<h4>Methods</h4>We developed a colorectal cancer (CRC)-specific OTS neoantigen panel by integrating TCGA mutation data with HLA class I binding predictions across 68 alleles (18 HLA-A, 34 HLA-B, and 16 HLA-C), covering both Asian and Caucasian populations. Candidate neoantigens were evaluated in a Vietnamese CRC cohort (n = 67) based on mutation and HLA matching.
What they did: Functional immunogenicity was assessed in patient-derived CD8⁺ T cells using IFN-γ ELISpot assays and single-cell RNA sequencing.<h4>Results</h4>The resulting panel comprised 73 recurrent nonsynonymous mutations, each generating at least one predicted HLA-I-restricted neoepitope, achieving >90% population coverage in both Asian and Caucasian groups. In the Vietnamese CRC cohort, 58% of patients harbored at least one matched neoantigen, with mutation frequency strongly correlating with predicted HLA presentation, particularly for HLA-A alleles. Functional validation in seven patients demonstrated robust CD8<sup>+</sup> T-cell responses against TP53_R273H.
Results & conclusions: Neoantigen-reactive T cells exhibited transcriptional signatures consistent with cytotoxic effector function and stem-like memory phenotypes.<h4>Discussion</h4>These findings identify TP53_R273H as a clinically relevant shared neoantigen in CRC and support the translational feasibility of a population-tailored OTS neoantigen panel. Our integrative computational and experimental framework highlights the importance of combining population-level HLA coverage with functional validation to advance broadly applicable neoantigen-based immunotherapies.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1686224 · PubMed 41789101.
Why it matters for pharma & biotech
- Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: vaccines
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Frontiers in Immunology study find?
Our integrative computational and experimental framework highlights the importance of combining population-level HLA coverage with functional validation to advance broadly applicable neoantigen-based immunotherapies.
What type of study is this?
It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Functional immunogenicity was assessed in patient-derived CD8⁺ T cells using IFN-γ ELISpot assays and single-cell RNA sequencing.<h4>Results</h4>The resulting panel comprised 73 recurrent nonsynonymous mutations, each generating at least one predicted HLA-I-restricted neoepitope, achieving >90% population coverage in both Asian and Caucasian groups.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1686224. PubMed ID: 41789101. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/identification-of-public-neoantigens-with-broad-hla-class-i-coverage-as-686224/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides